Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Observation × Clear all

Phase

Phase 3 54 Phase 2 42 Phase NA 15 Phase EARLY_PHASE1 3 Phase 4 2 Phase 2/3 2 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pathologic Complete Response 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 541 pembrolizumab 424 Paclitaxel 386 Gemcitabine 367 Cisplatin 365 Carboplatin 360 Radiotherapy 324 fludarabine 310 Nivolumab 288 Docetaxel 239 Bevacizumab 236 Irinotecan 210 Magnetic Resonance Spectroscopy 207 Dexamethasone 193 Specimen Handling 192 Fluorouracil 188 Capecitabine 184 Cytarabine 175 Rituximab 174 fludarabine phosphate 168 Biopsy 168 Temozolomide 167 Oxaliplatin 167 Ipilimumab 162 Etoposide 156 Lenalidomide 154 Doxorubicin 147 Cetuximab 145 Radiation 143 Leucovorin 142

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743555 2024-12-20

SAVED LUNG

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 1 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡